Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.01)
# 3,079
Out of 4,981 analysts
51
Total ratings
35.9%
Success rate
-1.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $18.94 | - | 3 | Sep 8, 2025 | |
| LEGN Legend Biotech | Assumes: Overweight | $55 → $66 | $33.11 | +99.34% | 1 | Aug 27, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $31.67 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $44.74 | +114.57% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $8.21 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $65.62 | - | 2 | Jun 10, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $5.82 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $4.37 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $11.73 | +10.91% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $3.31 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $56.26 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $83.10 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $36.77 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.53 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $35.69 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $144.86 | +101.57% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $394.53 | -6.22% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.69 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.26 | - | 1 | May 30, 2017 |
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.94
Upside: -
Legend Biotech
Aug 27, 2025
Assumes: Overweight
Price Target: $55 → $66
Current: $33.11
Upside: +99.34%
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $31.67
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $44.74
Upside: +114.57%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $8.21
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $65.62
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.82
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.37
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $11.73
Upside: +10.91%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.31
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $56.26
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $83.10
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.77
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.53
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $35.69
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $144.86
Upside: +101.57%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $394.53
Upside: -6.22%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.69
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.26
Upside: -